Quantify

Boston Scientific Corporation vs Pfizer, Inc. — Stock Comparison

Boston Scientific Corporation (BSX) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.

vs
Q·Score Winner
Boston Scientific Corporation
BSX8.5/10vs 6.4/10

Boston Scientific Corporation clearly outscores Pfizer, Inc. on Q·Score (8.5 vs 6.4 out of 10), led by Growth (8.8 vs 5.1) and Sentiment (8.5 vs 5.3). Analyst consensus targets imply greater upside for BSX (+70.2%) than for PFE (+15.8%).

Price Performance

Normalised to 100 at period start — shows relative performance.

Loading…
● BSX● PFE

Q·Score Breakdown

8.5
Very Bullish
Overall
6.4
Neutral
7.7
Quality
6.4
9.1
Health
7
8.8
Growth
5.1
8.6
Valuation
7.7
8.5
Sentiment
5.3
BSX

Clean balance sheet with low leverage (0.4× debt-to-equity).

PFE

Forward P/E of 8.9× is low relative to sector peers.

⚠ earnings contracting 10% year-over-year.

Analyst Consensus

Bullish
+70.2%
Target $77.10
30 analysts
Neutral
+15.8%
Target $29.19
27 analysts

Fundamentals

BSX
PFE
18.9×
Trailing P/E
19.2×
12.2×
Forward P/E
8.9×
17.29%
Profit Margin
11.83%
68.94%
Gross Margin
74.80%
14.66%
ROE
8.31%
11.60%
Revenue Growth
5.40%
100.00%
Earnings Growth
-10.10%
0.56
Beta
0.29
—
Dividend Yield
6.61%
$67.3B
Market Cap
$143.7B
52-Week Range
BSX
$441% of range$110
PFE
$2337% of range$29

Frequently Asked Questions

BSX vs PFE: which stock scores better overall?

Based on Q·Score, Boston Scientific Corporation (BSX) scores 8.5/10 versus Pfizer, Inc. (PFE) at 6.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.

Which has better revenue growth: BSX or PFE?

Boston Scientific Corporation (BSX) scores higher on Growth (8.8/10 vs 5.1/10). Boston Scientific Corporation reports revenue growth (11.6% YoY) while Pfizer, Inc. reports (5.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.

Is BSX or PFE more attractively valued?

Boston Scientific Corporation (BSX) scores higher on Valuation (8.6/10 vs 7.7/10). BSX trades at 12.2× P/E versus PFE at 8.9×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.

What do analysts say about BSX vs PFE?

There are 30 analysts covering BSX with a consensus price target of $77.10, and 27 analysts covering PFE with a consensus target of $29.19. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.

Which is more profitable: BSX or PFE?

Boston Scientific Corporation (BSX) scores higher on Quality (7.7/10 vs 6.4/10). Net profit margin: BSX at 17.3%, PFE at 11.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.

Which has stronger financial health: BSX or PFE?

Boston Scientific Corporation (BSX) scores higher on Financial Health (9.1/10 vs 7/10). Market beta: BSX at 0.56, PFE at 0.29. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.

What are the market caps of BSX and PFE?

Boston Scientific Corporation (BSX) has a market capitalisation of $67.3B, while Pfizer, Inc. (PFE) has a market cap of $143.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.

Do BSX or PFE pay dividends?

BSX does not currently pay a dividend, while PFE pays a dividend yield of 6.61%. Dividend yields fluctuate with share price and company payout decisions.

Related Comparisons

JNJ vs PFEMRNA vs PFELLY vs PFE

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →

Data provided by Yahoo Finance ·  Updated on each page load ·  For informational purposes only · Not financial advice · Quantify.biz © 2026